WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 14, 459-469. Review Article ISSN 2277–7105

TUBERCULOSIS AND ITS TREATMENT

***[1]Nilesh Bagal, [1]Utkarsh Bhamare, [1]Prasad Rodge, [1]Pratik Shirsath, [2]Mayur Bagul, [3]Swapnil Koli**

[1]Student, Department of Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India.

[2]Student, Department of Pharmacology, R. C. Patel Institute of Pharmacy, Shirpur, Dhule, Maharashtra, India.

[3]Student, Department of Pharmacology, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India.

Article Received on
28 May 2024,

Revised on 18 June 2024,
Accepted on 09 July 2024

DOI: 10.20959/wjpr202414-33209

***Corresponding Author**
Nilesh Bagal
Student, Department of Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra, India.

ABSTRACT

The infectious disease tuberculosis is mostly caused by Mycobacterium tuberculosis. It primarily affects the lungs, although it can also impact the brain and spine. People with TB in their lungs can sneeze, cough, or spit, which can spread the disease through the air. Although the illness is treatable and avoidable, it continues to be the leading cause of infection-related mortality worldwide, accounting for around 4500 deaths and 30,000 new cases per day. Tuberculosis (TB) is one of the deadliest and most ancient illnesses known to man. It continues to be a major global health, economic and social burden, particularly in low- and middle-income countries. In the treatment of tuberculosis, A six-month schedule comprising rifampicin, isoniazid, and pyrazinamide administered for two months, followed by rifampicin and isoniazid for four months, is the optimum course of action for individuals with fully susceptible organisms who comply with therapy. Unless the likelihood of medication resistance is low (i.e., the community has less than 4% primary isoniazid resistance, the patient has not previously received antituberculosis medication, is not from a nation where drug resistance is common, and has not been exposed to a drug-resistant case), the initial regimen should include ethambutol (or streptomycin in kids who are not old enough to have their visual acuity checked. Even in cases where the infecting organism exhibits resistance to INH, this

four-drug, six-month regimen remains successful. This advice is applicable to both HIV-positive and HIV-negative individuals. Nonetheless, evaluating the clinical and bacteriologic response is crucial when HIV infection is present. Therapy should be continued if there is evidence of a sluggish or subpar response, as determined case-by-case.

KEYWORDS: Mycobacterium tuberculosis, illnesses, mortality, resistance, rifampicin.

INTRODUCTION

The most common infectious disease affecting humans, tuberculosis (TB) is a major global source of illness and mortality. The Mycobacterium tuberculosis (M. tuberculosis) bacteria is the primary cause of this infectious disease.[1] Although its primary effect is on the lungs, tuberculosis can also damage the circulatory, lymphatic, and central neurological systems.[2] Apart from the microscopic examination and the culture of physiological fluids using microbes such as repeated sputum cultures, radiological techniques such as X-rays of the chest are generally utilized in the diagnosis process of active infectious tuberculosis.[3] On the other hand, the latent tuberculin infection diagnosis, wherein latent germs in the body do not produce symptoms, is made using the Mantoux tuberculin skin test and/or blood sample Interferon gamma release assays (IGRAs).[4] Vaccinations like the Bacillus Calmette Guerin (BCG) vaccine and screening programs are the mainstays of TB prevention.[5] Curing tuberculosis and stopping its spread as soon as possible are the two main objectives of treatment. This can only occur if the drugs used are able to sterilize the lesion, which stops disease relapse, stop naturally resistant strains from being selected, which stops drug resistance from developing during therapy, and quickly lower the bacillary population, which stops transmission.[6] Treatment success (patients who, under typical circumstances, recover at the conclusion of their treatment) the national average is roughly 70% (50–90%), although this varies greatly by region. This is despite the fact that treatments for tuberculosis can be up to 95% effective. Non adherence is one of the factors contributing to low effectiveness. It can manifest in three ways: treatment default, in which patients discontinue using all prescription drugs Incorrect medication use, in which patients take only a portion of the recommended dosage, or irregular medication use, in which people take the prescription only sometimes.[7]

TB Symptoms

- Fever
- Lymph node swelling
- Persistent (productive) cough

- Weight loss
- Abdominal or thoracic pain
- Hemoptysis
- Night sweats
- Abnormal fatigue [8]

The Clinical Manifestation of Tuberculosis

Latent Tuberculosis Infection (LTBI)

A crucial, non-replicating TB route infection is known as LTBI, and it opens. Although the afflicted individual does not exhibit any symptoms of the disease, immunological testing (for example, see "Diagnosis" below for interferon gamma released assays) yields positive results. Moreover, there are no signs of active tuberculosis in the diagnostic tests (least in terms of chest radiography). There is no infectious disease among these patients. However, LTBI might manifest as an illness at any time, if there is decreased T-cell immunity. During the first 18 months following M. tuberculosis infection, there is a 5% chance of developing clinically evident tuberculosis; the remaining 5% of the time, the risk is approximately 5%.[9]

Types of Disease

Pulmonary Tuberculosis

Frequent signs of pulmonary tuberculosis include hemoptysis, fever, sweats at night, excessive exhaustion and an intense cough. Compared to youngsters and immunocompromised persons, who may experience a rapid onset of fulminate tuberculosis, adults who are not immunocompromised experience a delayed course of the disease. When a cough lasts longer than three weeks, TB should always be taken into consideration (Box).[10]

Extrapulmonary and disseminated tuberculosis

Of all TB cases in Germany in 2017, 1375 (or 26%) were extrapulmonary alone. Extrapulmonary symptoms are becoming more common, according to recent statistics from a few developed nations. In certain parts of Spain, 37% of TB cases found in 2013 had this symptom.[11] The particular organ or organs implicated dictate the range and nature of the clinical symptoms. Adults without visible immune defects are increasingly being diagnosed with disseminated tuberculosis (TB), which affects more than two organ system. Before, this condition was almost exclusively seen in children or individuals with inhibition of the immune system. Immigrants from countries where the rate is moderate to high of tuberculosis comprise the majority of these patients. Those seeking Asylum and other individuals cannot

access the healthcare system due to language hurdles and frequent transfers, which can postpone diagnosis and hasten the course of illness.[12]

Multidrug-Resistant Tuberculosis

Although rare in the UK, certain tuberculosis strains exhibit resistance to two or more drugs. We call this multidrug-resistant tuberculosis.[13] Different strains of multidrug-resistant tuberculosis necessitate varying lengths of time for antibiotic treatment, ranging from 9 to 24 months. Multidrug-resistant tuberculosis typically has a poorer prognosis than regular tuberculosis.[14]

Latent Tuberculosis

You might have latent TB if you have TB bacteria but no symptoms of an active infection. Seek treatment if you are 65 years of age or younger and have latent tuberculosis. However, in older patients, liver damage can result from medications used to treat tuberculosis. The benefits and downsides of treating latent tuberculosis will be discussed with your TB team if you are between the ages of 35 and 65 and have concerns about liver damage. If latent tuberculosis is suspected of being medication resistant, therapy is usually not given. If this is the case, you may be monitored frequently in order to prevent the illness from returning.[15] Individuals who require immune-suppressive treatments such as long-term steroids, chemotherapy, or biological inhibitors like TNF inhibitors may benefit from being tested and treated for latent tuberculosis. This is due to the likelihood that the infection would spread aggressively.[16]

Treatment for latent TB generally involves

It is recommended to use isoniazid either by itself for six months in conjunction with rifampicin for three months.



Figure 1: Pulmonary tuberculosis with a big hollow (arrow) in upper field of the right lung (chest radiograph, perpendicular view)



Figure 2: Extrapulmonary manifestation of tuberculosis (TB) with abscess formulation around the abdominal aorta and upper field of the right ling (chest radiograph, p.a. view)

Tuberculosis Tests and Diagnosis

Two standard tests are used to detect tuberculosis

Blood test

These tests, commonly known as interferon-gamma release assays (IGRAs), measure how your body responds to TB proteins in mixed with a small quantity of blood.[18]

Skin test

The Mantoux skin test for tuberculin is another name for this. An injection of small amounts fluid is given by a technician into your lower arm. They will check your arm for swelling in two or three days. Positive results probably indicate the presence of tuberculosis-causing bacteria. A false positive, however, is also conceivable. The test may indicate that you have tuberculosis (TB) infection even when you have not had the Bacillus Calmette-Guerin (BCG) vaccination. If you've just come into contact with the virus, the findings could potentially be false negative, which would indicate that you do not actually have tuberculosis. You might take this test more than once.[17]

Method

Therapy for Tuberculosis

Your infection will determine how you are treated. Your physician will recommend medicine to eradicate the germs and prevent the infection from becoming active in order to treat latent

tuberculosis. You may receive isoniazid, rifampicin, or rifampicin alone or in combination. The medications may need to be taken for up to nine months. As soon as you notice any signs of active tuberculosis, notify your doctor. In addition, a mix of medications is used to treat active TB. The most widely used ones include rifampicin, pyrazinamide, isoniazid, and ethambutol. For 6 to 12 months, you will take them. If you have tuberculosis that is resistant to drugs, your doctor may recommend one or more other treatments. They can have additional adverse effects and require you to take them for up to 30 months.[19]

Tuberculosis treatment in adults

Two anti-tuberculosis medications were employed in 1940, when the Brazilian National Campaign against Tuberculosis was launched: para-amino salicylic acid and streptomycin. Brazil decided to utilize streptomycin and isoniazid twice a week in the 1950s. Bacterial resistance and an increase in tuberculosis-related fatalities led to the introduction of the 18-month HSZ regimen in the 1960s, which involves the application of pyrazinamide (Z), streptomycin (S), and isoniazid (H) over the duration of the treatment.[20] The RHZ regimen, which consisted of isoniazid (H), rifampicin (R) and pyrazinamide (Z) for 6 months, was developed as a short-term anti-tuberculosis treatment in the mid-1970s. The 6-month program was originally implemented in Brazil, the first nation in the world to do so—which offers free and point-of-care administration of all medications—into the public health care system.[21] Combination RH capsules were first introduced in the 1980s with the goal of stopping the development of acquired bacterial resistance.[22] Based on the preliminary results of the Second National Survey on Anti-TB Drug Resistance, which showed a rise in isoniazid primary resistance (from 4.4% to 6.0%), Brazil added ethambutol (E) to the RHZ regimen, as defined by PNCT, and started using fixed-dose combination (FDC) tablets in 2009.[23] Furthermore, no bioavailability or bio equivalency tests were conducted prior to the reduction of the tablet's pyrazinamide and isoniazid dosages (from 2,000 mg to 1,600 mg and 400 mg to 300 mg, respectively) during the treatment shift. This was in addition to the revised presentation that was given to FDC.[24] The basic treatment plan that is currently in use in Brazil for people with tuberculosis who do not have a clinical suspicion of medication resistance is described in. It is used for all kinds of the condition in patients older than 10 years. The FDC RHZE regimen is used for two months during the intensive phase, and the FDC RH regimen is used for four months during the maintenance phase. The exception is patients with meningitis associated with TB. These patients take a combination of oral medications for four weeks (prednisone at a rate of 1-2 mg/kg/day) throughout the

maintenance phase of treatment and intravenous (dexamethasone, administered for 4–8 weeks at a rate of 0.3–0.4 mg/kg/day) corticosteroids. Treatment lasts for 7 months. FDC tablets containing the medicines are available. 150 mg of rifampicin, 75 mg of isoniazid, 400 mg of pyrazinamide, and 275 mg of ethambutol are all present in each tablet.[25]

Tuberculosis treatment in children

Three distinct drugs are used in Brazil to treat patients under the age of ten: pyrazinamide (35 mg/kg), isoniazid (10 mg/kg), and rifampicin (10 mg/kg). This choice was made in light of the risk of ethambutol-induced visual impairment in children, which may challenging to diagnose, and the decreased risk of isoniazid resistance in individuals with low levels of bacteria, which is more common in pediatric tuberculosis patients.[26] The American Academy of Pediatrics advises monitoring visual acuity and the ability to distinguish somewhere between the hues of red and green during the intense phase of treatment, in addition to the four-drug regimen with the inclusion of ethambutol, based on systematic evaluations of the literature. In the absence of any other contraindication, ethambutol is a commonly prescribed treatment for infants and children with active tuberculosis. This being noted, the ratio of risk to benefit of ethambutol use should be taken into consideration in situations of children whose visual acuity cannot be checked.[27] The World Health Organization recommends using a three-drug regimen (RHZ regimen) without ethambutol during the induction phase of treatment for HIV-negative children with pulmonary tuberculosis who live in areas with low incidence of both HIV infection and isoniazid resistance. Children living in areas with high rates of HIV infection and/or isoniazid resistance should have ethambutol added to their regimen during the induction phase.[28]

DISCUSSION

The findings indicate that individuals with a possible cough, other neighborhood residents, and Traditional healers knew there was a treatment for tuberculosis in hospitals. However, individuals with suspected tuberculosis (TB) who have coughed for longer than 14 days did not visit medical facilities for a diagnosis or course of treatment.

CONCLUSION

Even though tuberculosis is currently uncommon in Germany, it is nonetheless important to remember this fact. Prompt therapy in conjunction with a timely specific diagnostic work-up can effectively stop the disease from spreading and spare the patient from a severe course of illness. The most common populations in developed nations to contract tuberculosis (TB) are

immigrants and those with compromised immune systems. The range of people at risk is expanded by the increasing use of immunosuppressive medications to treat a variety of ailments. In order to provide these individuals with preventive treatment, latent tuberculosis infection (LTBI) is being found more often using IFN-γ release assays (IGRA).

REFERENCES

1. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clinical microbiology reviews, Jul. 2003; 16(3): 463-96. DOI: https://doi.org/10.1128/cmr.16.3.463-496.2003
2. Be NA, Kim KS, Bishai WR, Jain SK. Pathogenesis of central nervous system tuberculosis. Current molecular medicine, Mar. 1, 2009; 9(2): 94-9. DOI: https://doi.org/10.2174/156652409787581655
3. Ko Y, Lee HY, Park YB, Hong SJ, Shin JH, Choi SJ, Kim C, Park SY, Jeong JY. Correlation of microbiological yield with radiographic activity on chest computed tomography in cases of suspected pulmonary tuberculosis. Plos one, Aug 9, 2018; 13(8): e0201748. DOI: https://doi.org/10.1371/journal.pone.0201748
4. Muñoz L, Stagg HR, Abubakar I. Diagnosis and management of latent tuberculosis infection. Cold Spring Harbor perspectives in medicine, Nov 1, 2015; 5(11): a017830. DOI: 10.1101/cshperspect.a017830
5. Pooransingh S, Sakhamuri S. Need for BCG vaccination to prevent TB in high-incidence countries and populations. Emerging Infectious Diseases, Mar. 2020; 26(3): 624. DOI: 10.3201/eid2603.191232
6. Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harbor perspectives in medicine, May. 1, 2015; 5(5): a017822. DOI: 10.1101/cshperspect.a017822
7. Stewart SJ, Moon Z, Horne R. Medication nonadherence: health impact, prevalence, correlates and interventions. Psychology & health, Jun. 3, 2023; 38(6): 726-65. DOI: https://doi.org/10.1080/08870446.2022.2144923
8. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, Sodemann M. TB score: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scandinavian journal of infectious diseases, Jan. 1, 2008; 40(2): 111-20. DOI: https://doi.org/10.1080/00365540701558698
9. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis

reactivation and their managements. Emerging microbes & infections, Jan. 1, 2016; 5(1): 1-8. DOI: https://doi.org/10.1038/emi.2016.10

10. Campbell IA, Bah-Sow O. Pulmonary tuberculosis: diagnosis and treatment. Bmj, May 18, 2006; 332(7551): 1194-7. DOI: https://doi.org/10.1136/bmj.332.7551.1194
11. Wetzstein N, Drummer AP, Bockey A, Herrmann E, Küpper-Tetzel CP, Graf C, Koch B, Goetsch U, Vehreschild MJ, Guglielmetti L, Lange B. Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, Jun. 2023; 51(3): 679-87. DOI: https://doi.org/10.1007/s15010-022-01921-9
12. Lodden Kemper R, Lipman M, Zumla A. Clinical aspects of adult tuberculosis. Cold Spring Harbor perspectives in medicine, Jan. 1, 2016; 6(1): a017848. DOI: 10.1101/cshperspect.a017848
13. Williams B, Ramroop S, Shah P, Anderson L, Das S, Riddell A, Liebeschuetz S, Roy RB, O'Callaghan M, Sloper K, Bernatoniene J. Multidrug-resistant tuberculosis in UK children: presentation, management and outcome. European Respiratory Journal, Jun. 1, 2013; 41(6): 1456-8. DOI: 10.1183/09031936.00179712
14. Pontali E, Raviglione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. European Respiratory Review, Jun. 30, 2019; 28(152). DOI: 10.1183/16000617.0035-2019
15. Noh CS, Kim HI, Choi H, Kim Y, Kim CH, Choi JH, Hyun IG, Baek MS. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. Respiratory medicine, Oct. 1, 2019; 157: 52-8. DOI: https://doi.org/10.1016/j.rmed.2019.09.004
16. Esmail H, Barry III CE, Wilkinson RJ. Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug discovery today, May. 1, 2012; 17(9-10): 514-21. DOI: https://doi.org/10.1016/j.drudis.2011.12.013
17. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria. The International Journal of Tuberculosis and Lung Disease, Nov. 1, 2006; 10(11): 1192-204.
18. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. American journal of respiratory and critical care medicine, Jul. 1, 2004; 170(1): 65-9. DOI: https://doi.org/10.1164/rccm.200402-232OC
19. Huaman MA, Sterling TR. Treatment of latent tuberculosis infection—an update. Clinics

in chest medicine, Dec. 1, 2019; 40(4): 839-48. DOI: https://doi.org/10.1016/j.ccm.2019.07.008

20. Rabahi MF, Silva JL, Ferreira AC, Tannus-Silva DG, Conde MB. Tuberculosis treatment. Jornal brasileiro de pneumologia, Nov. 43, 2017; 472-86. DOI: https://doi.org/10.1590/S1806-37562016000000388
21. Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Dec. 2009; 29(12): 1468-81. DOI: https://doi.org/10.1592/phco.29.12.1468
22. Paulus HE. History of combination therapy of rheumatoid arthritis. The Journal of rheumatology. Supplement, Mar. 1, 1996; 44: 38-42.
23. Arriaga MB, Torres NM, Araujo NC, Caldas SC, Andrade BB, Netto EM. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study. PLoS One, Dec. 26, 2019; 14(12): e0227101. DOI: https://doi.org/10.1371/journal.pone.0227101
24. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. International journal of clinical pharmacology and therapeutics, Oct. 1, 2002; 40(10): 474-81. DOI: https://doi.org/10.5414/cpp40474
25. Ballestero JG, Garcia JM, Bollela VR, Ruffino-Netto A, Dalcolmo MM, Moncaio AC, Miguel NS, Rigolin IZ, Palha PF. Management of multidrug-resistant tuberculosis: main recommendations of the Brazilian guidelines. Jornal Brasileiro de Pneumologia, May 11, 2020; 46: e20190290. DOI: https://doi.org/10.36416/1806-3756/e20190290
26. Maciel EL, Guidoni LM, Favero JL, Hadad DJ, Molino LP, Jonhson JL, Dietze R. Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. Jornal Brasileiro de Pneumologia, 2010; 36: 232-8. DOI: https://doi.org/10.1590/S1806-37132010000200012
27. Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. European Respiratory Journal, Oct. 1, 2016; 48(4): 963-71. DOI: 10.1183/13993003.01356-2016
28. Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C. Tuberculosis and

HIV co-infection in children. BMC infectious diseases, Jan. 2014; 14: 1-0. DOI: https://doi.org/10.1186/1471-2334-14-S1-S5